# Bobby Sandage > Bobby Sandage is a Series A investor at Paula and Rodger Riney Foundation backing Genetics. See 2 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Paula and Rodger Riney Foundation](https://shizune.co/investors/profile/paula-and-rodger-riney-foundation) - Location: St Louis, United States - Total investments: 2 - Last investment: Nov 2021 - Lead investor: 50% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/pub/bobby-w-sandage-jr-phd/11/872/690 Bobby Sandage is a Series A investor at Paula and Rodger Riney Foundation in St Louis focused on Genetics and Health Care. Dr. Bobby Sandage is the Managing Director of Paula and Rodger Riney Foundation. He is also a General Partner at Cultivation Capital and the President and CEO of Euclises Pharmaceuticals. Dr. Bobby Sandage most recently was President and CEO and member of the board for Coronado BioSciences, Inc. (CNDO) from March 2011 to April 2013. Previously, hewas vice president of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program from March 2010 to March 2011. From 1991 until 2009 (when Endo Pharmaceuticals acquired Indevus), Dr. Sandage was the Chief Scientific Officer and executive vice president of research and development, quality and manufacturing at Indevus Pharmaceuticals. He previously held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals. Dr. Sandage received his Ph.D. in Clinical Pharmacy from Purdue University and his B.S. in Pharmacy from the University of Arkansas. Dr. Sandage is also a registered pharmacist. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Genetics | 1 | 50% | | Health Care | 1 | 50% | | Biotechnology | 1 | 50% | | Health Diagnostics | 1 | 50% | ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 1 | 50% | | Series B | 1 | 50% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series B | Nov 16, 2021 | | | Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $6.9M | Series A | Oct 02, 2019 | | 2 of 2 investments shown. ## Co-investors - [Lightchain](https://shizune.co/investors/profile/lightchain) — VC Fund, 2 deals together - [NT Asset](https://shizune.co/investors/profile/nt-asset) — VC Fund, 2 deals together - [BioGenerator](https://shizune.co/investors/profile/biogenerator) — VC Fund, 1 deal together - [Innovatus Capital Partners](https://shizune.co/investors/profile/innovatus-capital-partners) — VC Fund, 1 deal together - [LabCorp](https://shizune.co/investors/profile/laboratory-corporation-of-america) — VC Fund, 1 deal together - [Morningside](https://shizune.co/investors/profile/morningside-technology-ventures) — VC Fund, 1 deal together ## About Paula and Rodger Riney Foundation VC Fund 1 contacts available at Paula and Rodger Riney Foundation. | Name | Title | Profile | | --- | --- | --- | | Bobby Sandage | Managing Director | https://shizune.co/investors/profile/bobby-w-sandage | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Bobby Sandage invest in? Bobby Sandage invests primarily in Genetics, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Bobby Sandage last invest? The most recent investment recorded for Bobby Sandage closed in Nov 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co